On Thursday, Shares of Energen Corp. (NYSE:EGN), gained 1.73% to $62.47.
Energen Corporation, will host a conference call on Friday, August 7, 2015, at 11:00 a.m. ET to talk about its second quarter 2015 financial and operating results. Earnings are predictable to be released after the market closes on Thursday, August 6, 2015.
Energen Corporation, through its partner Energen Resources Corporation, explores for, develops, and produces oil, natural gas, and natural gas liquids in the United States. As of December 31, 2014, the company had about 372.7 million barrels of oil equivalent reserves located in the Permian Basin in west Texas, and the San Juan Basin in New Mexico and Colorado. Energen Corporation was founded in 1929 and is headquartered in Birmingham, Alabama.
Shares of Orange SA (ADR) (NYSE:ORAN), inclined 1.16% to $14.82, during its last trading session.
Orange Business Services, declared that it has reached an agreement with Tata Communications to expand its network footprint in India. The Network-to-Network Interconnect (NNI) agreement is part of a planned partnership between the two companies and will enhance Orange domestic coverage ten-fold to over 120 cities to meet customer demand.
The NNI will enable Orange to utilize Tata Communications’ 120 points of presence (PoPs), extending Orange Business Services’ reach to tier-two and tier-three cities such as Bhopal, Kanpur and Visakhapatnam. The raised domestic footprint of the Orange network in India is particularly suited to support the expansion plans of global multinational customers looking to connect to the farthest corners of India with robust and reliable network services, featuring global service level agreements (SLA) and straightforward billing.
Orange provides a range of fixed telephony and mobile telecommunications, data transmission, and other value-added services to consumers, businesses, and other telecommunications operators worldwide.
At the end of Thursday’s trade, Shares of Sanofi SA (ADR) (NYSE:SNY), lost 1.50% to $48.78.
Sanofi, declared that the Phase 3 ODYSSEY JAPAN trial of the investigational therapy Praluent (alirocumab) Injection met its primary endpoint. At week 24, patients in the Praluent group practiced an average 64 percent greater reduction from baseline in their bad cholesterol, known as low-density lipoprotein cholesterol (LDL-C), when added to current standard of care counting statins, contrast to standard of care alone (p less than 0.0001). Patients were started on the lower dose of 75 mg, with the option to adjust their dose to 150 mg if they had not achieved their LDL-C aim (as defined by the Japan Atherosclerosis Society guidelines) at week 8. At week 24, 97 percent of patients in the Praluent group reached their LDL-C treatment aim, contrast to 10 percent for placebo (p less than 0.0001). Ninety-nine percent of patients treated with Praluent remained on the lower dose; two patients required adjustment to the higher dose.
The trial involved 216 Japanese patients with hypercholesterolemia at high cardiovascular (CV) risk and/or with an inherited form of high cholesterol known as heterozygous familial hypercholesterolemia (HeFH). Results were presented recently for the first time at the Annual Scientific Meeting of the Japan Atherosclerosis Society (JAS) in Sendai, Japan. Praluent is an investigational fully human monoclonal antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9).
Sanofi researches, develops, and markets various therapeutic solutions. Its products comprise diabetes solutions, counting Lantus, Apidra, and Insuman that are human insulin analogs; Amaryl, an oral sulfonylurea; Lyxumia, a glucagon-like peptide-1 receptor agonist; and Afrezza, an inhaled insulin to improve glycemic control, in addition to Toujeo, an insulin glargine.
Finally, Alamos Gold Inc. (NYSE:AGI), ended its last trade with -2.05% loss, and closed at $4.78.
Alamos Gold, planned to release its second quarter 2015 financial results before the start of trading on Wednesday, August 12, 2015. Senior administration will host a conference call at 12:00 pm ET on that day to talk about the results.
Alamos Gold Inc., a gold mining company, engages in the exploration, mine development, and mining and extraction of precious metals, primarily gold. The company’s primary asset is the Mulatos mine covering about 28,773 hectares of concessions in the state of Sonora, Mexico.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
